Related Experiment Video

Updated: Feb 27, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Targeting STAT3 with silibinin to improve cancer therapeutics

Joaquim Bosch-Barrera1, Bernardo Queralt1, Javier A Menendez2

  • 1Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Catalonia, Spain; Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.

Cancer Treatment Reviews
|July 8, 2017
PubMed

Insights

Silibinin, a natural compound, may overcome cancer drug resistance by inhibiting Signal transducer and activator of transcription 3 (STAT3). This could improve cancer treatment efficacy and reduce therapy toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a key factor in cancer drug resistance to various therapies.
  • Existing STAT3 inhibitors show limited clinical efficacy, hindering their therapeutic application.
  • Silibinin, derived from milk thistle, is a natural compound with potential STAT3-modulating properties.

Purpose of the Study:

  • To review the evidence for silibinin as a natural STAT3 inhibitor.
  • To examine silibinin's role in reducing cancer treatment toxicity and overcoming drug resistance.
  • To present preliminary clinical data on silibinin in cancer patients.

Main Methods:

  • Literature review of studies on silibinin and STAT3.
  • Analysis of silibinin's mechanisms in reversing cancer cell resistance.
  • Brief overview of clinical trial data involving silibinin-containing nutraceuticals.

Main Results:

  • Silibinin demonstrates the ability to down-modulate STAT3 activity.
  • Evidence suggests silibinin can mitigate cancer treatment toxicity.
  • Silibinin shows potential in reversing STAT3-mediated tumor resistance.

Conclusions:

  • Silibinin is a promising natural agent for targeting STAT3 in cancer therapy.
  • Further research into silibinin could lead to strategies against STAT3-mediated drug resistance.
  • Clinical data suggests potential benefits of silibinin in cancer patients.
Keywords:
CancerChemotherapyLegasil®RadiotherapySTAT3Silibinin

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K